Cardiomyopathy, Hypertrophic
"Cardiomyopathy, Hypertrophic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).
MeSH Number(s)
C14.280.238.100
C14.280.484.150.070.160
Concept/Terms
Cardiomyopathy, Hypertrophic- Cardiomyopathy, Hypertrophic
- Cardiomyopathies, Hypertrophic
- Hypertrophic Cardiomyopathies
- Hypertrophic Cardiomyopathy
- Cardiomyopathy, Hypertrophic Obstructive
- Cardiomyopathies, Hypertrophic Obstructive
- Hypertrophic Obstructive Cardiomyopathies
- Hypertrophic Obstructive Cardiomyopathy
- Obstructive Cardiomyopathies, Hypertrophic
- Obstructive Cardiomyopathy, Hypertrophic
Idiopathic Hypertrophic Subaortic Stenosis- Idiopathic Hypertrophic Subaortic Stenosis
- IHSS
- IHSSs
- Subvalvular Stenosis, Idiopathic Hypertrophic
- Hypertrophic Cardiomyopathy, Idiopathic
- Cardiomyopathies, Idiopathic Hypertrophic
- Cardiomyopathy, Idiopathic Hypertrophic
- Hypertrophic Cardiomyopathies, Idiopathic
- Idiopathic Hypertrophic Cardiomyopathies
- Idiopathic Hypertrophic Cardiomyopathy
- Hypertrophic Obstructive Cardiomyopathy (HOCM)
- Cardiomyopathies, Hypertrophic Obstructive (HOCM)
- Cardiomyopathy, Hypertrophic Obstructive (HOCM)
- Hypertrophic Obstructive Cardiomyopathies (HOCM)
- Idiopathic Hypertrophic Subvalvular Stenosis
- Idiopathic Hypertrophic Subaortic Stenosis (IHSS)
Asymmetric Septal Hypertrophy- Asymmetric Septal Hypertrophy
- Asymmetric Septal Hypertrophies
- Hypertrophies, Asymmetric Septal
- Hypertrophy, Asymmetric Septal
- Septal Hypertrophies, Asymmetric
- Septal Hypertrophy, Asymmetric
Below are MeSH descriptors whose meaning is more general than "Cardiomyopathy, Hypertrophic".
Below are MeSH descriptors whose meaning is more specific than "Cardiomyopathy, Hypertrophic".
This graph shows the total number of publications written about "Cardiomyopathy, Hypertrophic" by people in Harvard Catalyst Profiles by year, and whether "Cardiomyopathy, Hypertrophic" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 8 | 1 | 9 |
| 1995 | 9 | 0 | 9 |
| 1996 | 3 | 1 | 4 |
| 1997 | 8 | 0 | 8 |
| 1998 | 8 | 1 | 9 |
| 1999 | 7 | 2 | 9 |
| 2000 | 5 | 0 | 5 |
| 2001 | 4 | 2 | 6 |
| 2002 | 11 | 3 | 14 |
| 2003 | 5 | 1 | 6 |
| 2004 | 5 | 3 | 8 |
| 2005 | 14 | 2 | 16 |
| 2006 | 17 | 1 | 18 |
| 2007 | 9 | 0 | 9 |
| 2008 | 18 | 3 | 21 |
| 2009 | 15 | 2 | 17 |
| 2010 | 24 | 0 | 24 |
| 2011 | 24 | 1 | 25 |
| 2012 | 20 | 6 | 26 |
| 2013 | 11 | 3 | 14 |
| 2014 | 28 | 2 | 30 |
| 2015 | 15 | 0 | 15 |
| 2016 | 19 | 2 | 21 |
| 2017 | 22 | 5 | 27 |
| 2018 | 31 | 0 | 31 |
| 2019 | 25 | 1 | 26 |
| 2020 | 34 | 4 | 38 |
| 2021 | 42 | 2 | 44 |
| 2022 | 32 | 1 | 33 |
| 2023 | 39 | 0 | 39 |
| 2024 | 5 | 0 | 5 |
Below are the most recent publications written about "Cardiomyopathy, Hypertrophic" by people in Profiles.
-
Metabolic profiling of aortic stenosis and hypertrophic cardiomyopathy identifies mechanistic contrasts in substrate utilization. FASEB J. 2024 Mar 31; 38(6):e23505.
-
Genetic Testing in Hypertrophic Cardiomyopathy. Am J Cardiol. 2024 Feb 01; 212S:S4-S13.
-
Hypertrophic Cardiomyopathy: A Brief Overview. Am J Cardiol. 2024 Feb 01; 212S:S1-S3.
-
A systematic review of present and future pharmaco-structural therapies for hypertrophic cardiomyopathy. Clin Cardiol. 2024 Jan; 47(1):e24207.
-
Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort. JACC Heart Fail. 2024 Jan; 12(1):164-177.
-
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study Design. JACC Heart Fail. 2024 Jan; 12(1):199-215.
-
Prediction of worsening heart failure in hypertrophic cardiomyopathy using plasma proteomics. Heart. 2023 Nov 27; 109(24):1837-1843.
-
Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. Eur Heart J. 2023 Nov 21; 44(44):4622-4633.
-
Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM. Circulation. 2024 02 13; 149(7):498-509.
-
Meta-Analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy. Circulation. 2024 01 09; 149(2):107-123.